https://renovorx.com/wp-content/uploads/2025/02/SIR2024_Presentation_17-Mar-2024_draft-with-refs.pdf
A Nebraska Medicine oncologist discusses a clinical trial using a catheter-based approach designed to deliver chemotherapy near pancreatic tumors.
RenovoRx today announced its financial results for the third quarter ended September 30, 2026 and provided shareholders with a business update highlighting continued commercial momentum and clinical progress.
A Moffitt Cancer Center patient with locally advanced pancreatic cancer is regaining parts of his daily life after a treatment designed to deliver chemotherapy near the tumor.
RenovoRx today announced that it will release third quarter 2026 financial results and business highlights after market close on Thursday, November 5, 2026, and host a conference call and webcast at 4:30 p.m. ET.